These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10777144)

  • 21. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
    Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
    Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses.
    Ostrowski MA; Gu JX; Kovacs C; Freedman J; Luscher MA; MacDonald KS
    J Infect Dis; 2001 Nov; 184(10):1268-78. PubMed ID: 11679915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy.
    Keane NM; Price P; Stone SF; John M; Murray RJ; French MA
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1991-6. PubMed ID: 11153082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.
    Steers NJ; Peachman KK; McClain S; Alving CR; Rao M
    Vaccine; 2009 Nov; 27(49):6939-49. PubMed ID: 19748578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
    Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
    Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired Bacillus Calmette-Guérin cellular immune response in HIV-exposed, uninfected infants.
    Mazzola TN; da Silva MT; Abramczuk BM; Moreno YM; Lima SC; Zorzeto TQ; Passeto AS; Vilela MM
    AIDS; 2011 Nov; 25(17):2079-87. PubMed ID: 21866040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
    Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
    J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
    Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.
    Younes SA; Yassine-Diab B; Dumont AR; Boulassel MR; Grossman Z; Routy JP; Sekaly RP
    J Exp Med; 2003 Dec; 198(12):1909-22. PubMed ID: 14676302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.
    Tilton JC; Luskin MR; Johnson AJ; Manion M; Hallahan CW; Metcalf JA; McLaughlin M; Davey RT; Connors M
    J Virol; 2007 Mar; 81(6):2713-25. PubMed ID: 17182676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
    Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tumour necrosis factor-alpha (TNF-alpha) in the induction of HIV-1 gp120-mediated CD4+ T cell anergy.
    Kaneko H; Hishikawa T; Sekigawa I; Hashimoto H; Okumura K; Kaneko Y
    Clin Exp Immunol; 1997 Jul; 109(1):41-6. PubMed ID: 9218822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
    Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
    HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
    Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
    Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).
    Moss RB; Giermakowska W; Wallace MR; Savary J; Jensen F; Carlo DJ
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):724-7. PubMed ID: 10973444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Jensen FC; Maigetter RZ; Carlo DJ
    Clin Exp Immunol; 2001 May; 124(2):248-54. PubMed ID: 11422201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.